CD19 and hematologic disorder: It has shown impressive response rates in CD19+ R/R hematological malignancies, especially in B-cell acute lymphoblastic leukemia (B-ALL), non-Hodgkin’s lymphoma (NHL), and chronic lymphocytic leukemia (CLL).